Belite Bio, Inc (NASDAQ:BLTE) Forecasted to Earn Q1 2025 Earnings of ($0.29) Per Share

Belite Bio, Inc (NASDAQ:BLTE) – Stock analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Belite Bio in a report issued on Tuesday, August 13th. HC Wainwright analyst Y. Chen expects that the company will earn ($0.29) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $60.00 target price on the stock. The consensus estimate for Belite Bio’s current full-year earnings is ($1.08) per share. HC Wainwright also issued estimates for Belite Bio’s Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.29) EPS and Q4 2025 earnings at ($0.29) EPS.

Belite Bio (NASDAQ:BLTE) last released its quarterly earnings results on Monday, May 13th. The company reported ($0.27) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.07.

A number of other research firms have also weighed in on BLTE. Benchmark reaffirmed a “buy” rating and set a $57.00 price target on shares of Belite Bio in a report on Tuesday. Cantor Fitzgerald restated an “overweight” rating on shares of Belite Bio in a research note on Thursday, June 20th.

Belite Bio Price Performance

BLTE opened at $49.90 on Wednesday. The firm’s 50 day moving average is $48.48 and its 200-day moving average is $44.97. Belite Bio has a 52-week low of $21.01 and a 52-week high of $50.66. The firm has a market capitalization of $1.49 billion, a P/E ratio of -42.29 and a beta of -1.47.

Institutional Trading of Belite Bio

A hedge fund recently bought a new stake in Belite Bio stock. Armistice Capital LLC acquired a new position in shares of Belite Bio, Inc (NASDAQ:BLTE) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 36,000 shares of the company’s stock, valued at approximately $1,647,000. Armistice Capital LLC owned approximately 0.13% of Belite Bio at the end of the most recent reporting period. 0.53% of the stock is currently owned by hedge funds and other institutional investors.

About Belite Bio

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.